MicroRNA-145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma

Molecular Medicine Reports

Volumn 10, Issue 1, 2014, Pages 393-398

  Wu, Deyao ^a   Li, Min ^a   Wang, Linmao ^a   Zhou, Yunfeng ^a   Zhou, Jian ^a   Pan, Huixing ^a   Qu, Ping ^a  

^a NANTONG MEDICAL COLLEGE   (China)

Author keywords

Matrix metallopeptidase 11; MicroRNA 145; Renal cell carcinoma

Indexed keywords

MICRORNA 145; STROMELYSIN 3; 3' UNTRANSLATED REGION; MICRORNA; MIRN145 MICRORNA, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CANCER INHIBITION; CELL INVASION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL EVALUATION; DOWN REGULATION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUCIFERASE ASSAY; METASTASIS; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN TARGETING; SUPPRESSOR CELL; UPREGULATION; WESTERN BLOTTING; 3' UNTRANSLATED REGION; CELL MOTION; CHEMISTRY; GENETICS; KIDNEY TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 11; MICRORNAS; TRANSFECTION;

EID: 84901469282     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2149     Document Type: Article

References (53)

1. Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62: 220-241, 2012.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
4. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
5. Yan BC, Mackinnon AC and Al-Ahmadie HA: Recent developments in the pathology of renal tumors: morphology and molecular characteristics of select entities. Arch Pathol Lab Med 133: 1026-1032, 2009.
6. Yu ZH, Zhang Q, Wang YD, Chen J, Jiang ZM, Shi M, Guo X, Qin J, Cui GH, Cai ZM, et al: Overexpression of cyclooxygenase-1 correlates with poor prognosis in renal cell carcinoma. Asian Pac J Cancer Prev 14: 3729-3734, 2013.
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
8. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566, 2002. (Pubitemid 35402959)
9. Xue YJ, Xiao RH, Long DZ, Zou XF, Wang XN, Zhang GX, Yuan YH, Wu GQ, Yang J, Wu YT, et al: Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med 10: 200, 2012.
10. Choi YD, Kim KS, Ryu S, Park Y, Cho NH, Rha SH, Jang JJ, Ro JY, Juhng SW and Choi C: Claudin-7 is highly expressed in chromophobe renal cell carcinoma and renal oncocytoma. J Korean Med Sci 22: 305-310, 2007.
11. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, et al: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26: 4148-4157, 2007. (Pubitemid 46920170)
12. Yao Y, Charlesworth J, Nair V and Watson M: MicroRNA expression profiles in avian haemopoietic cells. Front Genet 4: 153, 2013.
13. Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20, 2005. (Pubitemid 40094598)
14. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
15. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
16. Yoo AS, Staahl BT, Chen L and Crabtree GR: MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature 460: 642-646, 2009.
17. le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, Anile C, Maira G, Mercatelli N, Ciafrè SA, et al: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 26: 3699-3708, 2007. (Pubitemid 47236875)
18. Zhang H, Li Y and Lai M: The microRNA network and tumor metastasis. Oncogene 29: 937-948, 2010.
19. Sachdeva M and Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2: 170-180, 2010.
20. Lagos-Quintana M, Rauhut R, Lendeckel W and Tuschl T: Identification of novel genes coding for small expressed RNAs. Science 294: 853-858, 2001. (Pubitemid 33032103)
21. Lakshmipathy U, Love B, Adams C, Thyagarajan B and Chesnut JD: Micro RNA profiling: an easy and rapid method to screen and characterize stem cell populations. Methods Mol Biol 407: 97-114, 2007.
22. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP and James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891, 2003. (Pubitemid 37288707)
23. Doberstein K, Steinmeyer N, Hartmetz AK, Eberhardt W, Mittelbronn M, Harter PN, Juengel E, Blaheta R, Pfeilschifter J and Gutwein P: MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 15: 218-230, 2013.
24. Ozen M, Creighton CJ, Ozdemir M and Ittmann M: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27: 1788-1793, 2008. (Pubitemid 351380263)
25. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, et al: Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125: 345-352, 2009.
26. Akao Y, Nakagawa Y and Naoe T: MicroRNA-143 and -145 in colon cancer. DNA Cell Biol 26: 311-320, 2007. (Pubitemid 46799180)
27. Akao Y, Nakagawa Y, Kitade Y, Kinoshita T and Naoe T: Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 98: 1914-1920, 2007. (Pubitemid 350002197)
28. Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T and Baserga R: Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 282: 32582-32590, 2007. (Pubitemid 350159311)
29. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K and Mo YY: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 106: 3207-3212, 2009.
30. Larsson E, Fredlund Fuchs P, Heldin J, Barkefors I, Bondjers C, Genové G, Arrondel C, Gerwins P, Kurschat C, Schermer B, et al: Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1. Genome Med 1: 108, 2009.
31. Sachdeva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70: 378-387, 2010.
32. Seoane J, Le HV and Massagué J: Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729-734, 2002. (Pubitemid 35177959)
33. Wang L, Tang H, Thayanithy V, Subramanian S, Oberg AL, Cunningham JM, Cerhan JR, Steer CJ and Thibodeau SN: Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69: 9490-9497, 2009.
34. Chen X, Gong J, Zeng H, Chen N, Huang R, Huang Y, Nie L, Xu M, Xia J, Zhao F, et al: MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 70: 2728-2738, 2010.
35. Kwon YJ, Hurst DR, Steg AD, Yuan K, Vaidya KS, Welch DR and Frost AR: Gli1 enhances migration and invasion via up-regulation of MMP-11 and promotes metastasis in ERalpha negative breast cancer cell lines. Clin Exp Metastasis 28: 437-449, 2011.
36. Yan D, Dai H and Liu JW: Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma. BMC Cancer 11: 151, 2011.
37. Li DQ, Shang TY, Kim HS, Solomon A, Lokeshwar BL and Pflugfelder SC: Regulated expression of collagenases MMP-1, -8, and -13 and stromelysins MMP-3, -10, and -11 by human corneal epithelial cells. Invest Ophthalmol Vis Sci 44: 2928-2936, 2003. (Pubitemid 36759754)
38. Kähäri VM and Saarialho-Kere U: Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 31: 34-45, 1999.
39. Clark AF: New discoveries on the roles of matrix metalloproteinases in ocular cell biology and pathology. Invest Ophthalmol Vis Sci 39: 2514-2516, 1998.
40. Wu D, Ding J, Wang L, Pan H, Zhou Z, Zhou J and Qu P: microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett 5: 829-834, 2013.
41. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58: 1395-1399, 1998. (Pubitemid 28193598)
42. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002. (Pubitemid 37328786)
43. Valdivia A, Peralta R, Matute-González M, Garcia Cebada JM, Casasola I, Jiménez-Medrano C, Aguado-Pérez R, Villegas V, Gonzalez-Bonilla C, Manuel-Apolinar L, et al: Co-expression of metalloproteinases 11 and 12 in cervical scrapes cells from cervical precursor lesions. Int J Clin Exp Pathol 4: 674-682, 2011.
44. Pan W, Arnone M, Kendall M, Grafstrom RH, Seitz SP, Wasserman ZR and Albright CF: Identification of peptide substrates for human MMP-11 (stromelysin-3) using phage display. J Biol Chem 278: 27820-27827, 2003. (Pubitemid 36899974)
45. Rouyer N, Wolf C, Chenard MP, Rio MC, Chambon P, Bellocq JP and Basset P: Stromelysin-3 gene expression in human cancer: an overview. Invasion Metastasis 14: 269-275, 1994.
46. Kossakowska AE, Huchcroft SA, Urbanski SJ and Edwards DR: Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant non-Hodgkin's lymphomas in humans. Br J Cancer 73: 1401-1408, 1996.
47. Têtu B, Brisson J, Lapointe H and Bernard P: Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Hum Pathol 29: 979-985, 1998. (Pubitemid 28422047)
48. Nöel AC, Lefebvre O, Maquoi E, VanHoorde L, Chenard MP, Mareel M, Foidart JM, Basset P and Rio MC: Stromelysin-3 expression promotes tumor take in nude mice. J Clin Invest 97: 1924-1930, 1996. (Pubitemid 26129880)
49. Masson R, Lefebvre O, Noël A, Fahime ME, Chenard MP, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart JM, et al: In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 140: 1535-1541, 1998. (Pubitemid 28153000)
50. Noël A, Boulay A, Kebers F, Kannan R, Hajitou A, Calberg-Bacq CM, Basset P, Rio MC and Foidart JM: Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 19: 1605-1612, 2000.
51. Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautès-Fridman C, Basset P and Rio MC: High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 61: 2189-2193, 2001. (Pubitemid 32692046)
52. Wu E, Mari BP, Wang F, Anderson IC, Sunday ME and Shipp MA: Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J Cell Biochem 82: 549-555, 2001. (Pubitemid 32720670)
53. Peruzzi D, Mori F, Conforti A, Lazzaro D, De Rinaldis E, Ciliberto G, La Monica N and Aurisicchio L: MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res 15: 4104-4113, 2009.